Psilocybin mushrooms Facts
Psychedelic;
Description
Psilocybin mushrooms (Psilocybe spp., Hymenogastraceae) — magic mushrooms, shrooms — are psychoactive fungi comprising roughly 165 species found on every continent except Antarctica.[1] The dominant alkaloid, psilocybin, is converted by the body into psilocin, the compound responsible for the psychedelic state. Psilocin activates serotonin receptors in the cortex, disrupting the brain's default resting network and generating the characteristic psychedelic experience.[2]
Subjective effects include brightened colors, geometric visual patterns, emotional enhancement, and — at higher doses — ego dissolution, where the sense of a separate self temporarily collapses.[3] The experience is shaped decisively by dose, psychological state, and environment; alkaloid content varies up to 11-fold within a single species.[4]
Psilocybin produces no physical dependence and no withdrawal;[5] acute physical toxicity at documented human doses is negligible.[6] The primary danger is psychological — difficult experiences at high doses — with lithium and MAOI co-administration posing the most serious drug interaction risks.[7]
Dose and duration
No dose or duration recorded for any route.
Body and dependence
- Acute toxicity
- Negligible
- Chronic toxicity
- Negligible
- Physical dependence
- None
- Psychological dependence
- Negligible
- Withdrawal
- None recorded
- Compulsive redosing
- Negligible
Tolerance
- Builds
- Rapid
- Fully resets after
- 7 days
- Carries over to
- LSD;
mescaline; DMT; other serotonergic hallucinogens
Effectslikely at a common dose
- Perception
- Color enhancement;
Visual drifting; Color alteration; Music enhancement; Auditory enhancement; Geometry; Visual breathing; Holotropic state; +25 possible, including Visual haze / noise, Spatial disorientation, Vestibular distortion - Body
- Nausea;
Pupil dilation; Body high; Body scan awareness; +28 possible, including Muscle tension, Dizziness, Excessive sweating - Thinking
- Thought connectivity;
Immersion enhancement; Aesthetic enhancement; Introspection enhancement; Openness enhancement; +29 possible, including Suggestibility enhancement, Confusion, Memory suppression - Feeling
- Emotional enhancement;
Euphoria; +7 possible, including Emotional lability, Anxiety, Paranoia - Self
- none likely · 12 possible, including Derealization, Communication suppression, Depersonalization
- Time
- Time alteration;
+4 possible, including Temporal disorientation - Transpersonal
- none likely · 1 possible
- Awareness
- none likely · 4 possible
Who shouldn't take it
Combinations61 recorded
Seek help immediately if
Most difficulty is psychological (intense fear, panic, confusion) and passes with calm support — the signs below mean seek emergency help:
- Very high body temperature; hot, dry skin
- Seizures
- Chest pain; fast or irregular heartbeat
- Severe muscle rigidity, tremor, or twitching (possible serotonin syndrome)
- Cold, pale, or blue fingers/toes — severe vasoconstriction (notably NBOMe / DOx)
- Persistent vomiting; unconsciousness; uncontrollable agitation or risk of self-harm
What to do
- Stay calm and reassure — remind them they took a drug and the effect will pass
- Move to a calm, quiet, safe space with low light; reduce noise and sensory input
- Keep them from harm — they may act on fear or confusion; stay with them, don't leave them alone
- Talk them down gently; don't grab or restrain unless they're in danger
- For the medical signs above (overheating, seizure, chest pain, vasoconstriction, unresponsive) call emergency services
- If overheating, cool the body; be ready to give rescue breaths / CPR
The experience is time-limited and usually resolves with calm reassurance in a safe setting — psychological first aid, not medication. Serious physical harm is uncommon for classic psychedelics (LSD, psilocybin) but real for some potent phenethylamines (NBOMe, DOx), where hyperthermia, seizures, and vasoconstriction warrant emergency care.
988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE
References
- [1]
- [2]^Madsen MK, Fisher PM, Burmester D, et al. (2019) Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels — Neuropsychopharmacology doi:10.1038/s41386-019-0324-9
- [3]^Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance — Psychopharmacology PMID:16826400
- [4]^Christiansen AL, Rasmussen KE, Høiland K (1981) The content of Psilocybin in Norwegian Psilocybe semilanceata — Planta Medica PMID:17401967
- [5]^Lodetti G, de Bitencourt RM, Rico EP (2024) Classic psychedelics and the treatment for alcoholism — Progress in Neuro-Psychopharmacology & Biological Psychiatry doi:10.1016/j.pnpbp.2024.111129
- [6]^Henríquez-Hernández LA, Rojas-Hernández J, Quintana Hernández DJ, Borkel LF (2023) Hofmann vs. Paracelsus: Do Psychedelics Defy the Basics of Toxicology? A Systematic Review — Toxics doi:10.3390/toxics11020148